Biomea Fusion, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMEA research report →
Companybiomeafusion.com
Biomea Fusion, Inc. , a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
- CEO
- Michael J. Hitchcock
- IPO
- 2021
- Employees
- 79
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $79.13M
- P/E
- -2.14
- P/S
- 0.00
- P/B
- 5.14
- EV/EBITDA
- -0.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -196.72%
- ROIC
- -173.69%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-61,797,000 · 55.36%
- EPS
- $-1.18 · 69.19%
- Op Income
- $-81,307,000
- FCF YoY
- 41.48%
Performance & Tape
- 52W High
- $3.08
- 52W Low
- $0.87
- 50D MA
- $1.54
- 200D MA
- $1.51
- Beta
- -0.34
- Avg Volume
- 1.54M
Get TickerSpark's AI analysis on BMEA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Erdtmann Rainer M | other | 452,512 |
| Apr 1, 26 | Hitchcock Michael J.M. | other | 667,477 |
| Dec 31, 25 | Erdtmann Rainer M | other | 0 |
| Dec 31, 25 | Erdtmann Rainer M | other | 0 |
| Dec 11, 25 | Erdtmann Rainer M | buy | 30,000 |
| Dec 2, 25 | Hitchcock Michael J.M. | buy | 100,000 |
| Dec 1, 25 | Erdtmann Rainer M | buy | 10,000 |
| Nov 28, 25 | Erdtmann Rainer M | buy | 40,000 |
| Aug 11, 25 | Hitchcock Michael J.M. | other | 916,434 |
| Aug 11, 25 | Erdtmann Rainer M | other | 1,246,989 |
Our BMEA Coverage
We haven't published any research on BMEA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BMEA Report →